Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
An update from Genmab ( (GMAB) ) is now available.
On September 23, 2025, Genmab A/S announced that Orbis Investment Management Limited now controls 5.03% of its share capital and voting rights, as of September 19, 2025. This major shareholder announcement highlights Orbis’s significant influence within Genmab, potentially impacting the company’s strategic decisions and market positioning.
The most recent analyst rating on (GMAB) stock is a Buy with a $43.00 price target. To see the full list of analyst forecasts on Genmab stock, see the GMAB Stock Forecast page.
Spark’s Take on GMAB Stock
According to Spark, TipRanks’ AI Analyst, GMAB is a Outperform.
Genmab’s overall stock score is driven by strong earnings call results and positive technical indicators, highlighting robust growth prospects and market momentum. The company’s solid financial performance, despite recent revenue and cash flow challenges, supports its stability. Valuation metrics suggest the stock is undervalued, offering potential upside. The absence of significant corporate events does not impact the score.
To see Spark’s full report on GMAB stock, click here.
More about Genmab
Genmab is an international biotechnology company focused on developing innovative and differentiated antibody therapeutics. Established in 1999 and headquartered in Copenhagen, Denmark, Genmab has a global presence across North America, Europe, and Asia Pacific. The company specializes in next-generation antibody technology platforms, including bispecific T-cell engagers and antibody-drug conjugates, aiming to transform the lives of patients with cancer and other serious diseases by 2030.
Average Trading Volume: 1,322,061
Technical Sentiment Signal: Buy
Current Market Cap: $17.68B
See more insights into GMAB stock on TipRanks’ Stock Analysis page.